{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:06:47Z","timestamp":1778551607634,"version":"3.51.4"},"reference-count":113,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Orally administered antipsychotic drugs are the first-line treatment for psychotic disorders, such as schizophrenia and bipolar disorder. Nevertheless, adverse drug reactions jeopardize clinical outcomes, resulting in patient non-compliance. The design formulation strategies for enhancing brain drug delivery has been a major challenge, mainly due to the restrictive properties of the blood\u2013brain barrier. However, recent pharmacokinetic and pharmacodynamic in vivo assays confirmed the advantage of the intranasal route when compared to oral and intravenous administration, as it allows direct nose-to-brain drug transport via neuronal pathways, reducing systemic side effects and maximizing therapeutic outcomes. In addition, the incorporation of antipsychotic drugs into nanosystems such as polymeric nanoparticles, polymeric mixed micelles, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, nanoemulgels, nanosuspensions, niosomes and spanlastics, has proven to be quite promising. The developed nanosystems, having a small and homogeneous particle size (ideal for nose-to-brain delivery), high encapsulation efficiency and good stability, resulted in improved brain bioavailability and therapeutic-like effects in animal models. Hence, although it is essential to continue research in this field, the intranasal delivery of nanosystems for the treatment of schizophrenia, bipolar disorder and other related disorders has proven to be quite promising, opening a path for future therapies with higher efficacy.<\/jats:p>","DOI":"10.3390\/pharmaceutics15020678","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T02:27:24Z","timestamp":1676600844000},"page":"678","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy"],"prefix":"10.3390","volume":"15","author":[{"given":"Maria Daniela","family":"Ferreira","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"given":"Joana","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"given":"Francisco","family":"Veiga","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"REQUIMTE\/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-6000","authenticated-orcid":false,"given":"Ana Cl\u00e1udia","family":"Paiva-Santos","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"REQUIMTE\/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-4894","authenticated-orcid":false,"given":"Patr\u00edcia C.","family":"Pires","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"REQUIMTE\/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Health Sciences Research Centre (CICS-UBI), University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1025414","DOI":"10.3389\/fpsyt.2022.1025414","article-title":"Crossroad between current knowledge and new perspective of diagnostic and therapy of late-onset schizophrenia and very late-onset schizophrenia-like psychosis: An update","volume":"13","author":"Nowak","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpsychires.2022.02.036","article-title":"Excess mortality in severe mental disorders: A systematic review and meta-regression","volume":"149","author":"Ali","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41398-021-01671-6","article-title":"Worldwide prevalence of suicidal ideation and suicide plan among people with schizophrenia: A meta-analysis and systematic review of epidemiological surveys","volume":"11","author":"Bai","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990\u20132019: A Systematic Analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(19)30934-1","article-title":"New WHO prevalence estimates of mental disorders in conflict settings: A systematic review and meta-analysis","volume":"394","author":"Charlson","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1024649","DOI":"10.3389\/fncel.2022.1024649","article-title":"The effects and mechanism of environmental enrichment on MK-801 induced cognitive impairment in rodents with schizophrenia","volume":"16","author":"Xu","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12991-022-00413-2","article-title":"Positive and negative syndrome scale in forensic patients with schizophrenia spectrum disorders: A systematic review and meta-analysis","volume":"21","author":"Buizza","year":"2022","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.schres.2021.08.001","article-title":"The association between vitamin D and symptom domains in psychotic disorders: A systematic review","volume":"237","author":"Tsiglopoulos","year":"2021","journal-title":"Schizophr. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.schres.2022.03.004","article-title":"Neurodegenerative model of schizophrenia: Growing evidence to support a revisit","volume":"243","author":"Stone","year":"2022","journal-title":"Schizophr. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s40265-019-01189-8","article-title":"Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder","volume":"79","author":"Azorin","year":"2019","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.2147\/NDT.S273503","article-title":"Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions","volume":"18","author":"Elsayed","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.schres.2022.01.047","article-title":"Guidelines for the management of psychosis in the context of mood disorders","volume":"241","author":"Bassett","year":"2022","journal-title":"Schizophr. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis","volume":"44","author":"McCutcheon","year":"2017","journal-title":"Schizophr. Bull."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/schbul\/sbaa055","article-title":"Striatal Dopamine and Reward Prediction Error Signaling in Unmedicated Schizophrenia Patients","volume":"46","author":"Katthagen","year":"2020","journal-title":"Schizophr. Bull."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biopsych.2016.05.021","article-title":"An Integrative Perspective on the Role of Dopamine in Schizophrenia","volume":"81","author":"Maia","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.biopsych.2022.06.017","article-title":"Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance","volume":"92","author":"Howes","year":"2022","journal-title":"Biol. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/brain\/awz093","article-title":"Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms","volume":"142","author":"Avram","year":"2019","journal-title":"Brain"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104608","DOI":"10.1016\/j.neubiorev.2022.104608","article-title":"Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends","volume":"136","author":"Sabe","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kamei, H. (2022). Polypharmacy Management of Antipsychotics in Patients with Schizophrenia. Medicina, 58.","DOI":"10.3390\/medicina58111584"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2019.05.030","article-title":"Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis","volume":"209","author":"Matsui","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.schres.2021.08.005","article-title":"Predictors of response to pharmacological treatments in treatment-resistant schizophrenia\u2014A systematic review and meta-analysis","volume":"236","author":"Lehtiniemi","year":"2021","journal-title":"Schizophr. Res."},{"key":"ref_23","first-page":"CD010219","article-title":"Selective noradrenaline reuptake inhibitors for schizophrenia","volume":"2018","author":"Matthews","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: A narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.neubiorev.2021.10.025","article-title":"The dual hit hypothesis of schizophrenia: Evidence from animal models","volume":"131","author":"Guerrin","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lian, L., Kim, D.D., Procyshyn, R.M., C\u00e1zares, D., Honer, W.G., and Barr, A.M. (2022). Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0267808"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41398-021-01636-9","article-title":"A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?","volume":"11","author":"Katona","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fabrazzo, M., Cipolla, S., Camerlengo, A., Perris, F., and Catapano, F. (2022). Second-Generation Antipsychotics\u2019 Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154530"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised, cohort, and pre\u2013post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/npr2.12286","article-title":"Recent findings on subjective well-being and physical, psychiatric, and social comorbidities in individuals with schizophrenia: A literature review","volume":"42","author":"He","year":"2022","journal-title":"Neuropsychopharmacol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2021.08.022","article-title":"Increased rates of respiratory disease in schizophrenia: A systematic review and meta-analysis including 619,214 individuals with schizophrenia and 52,159,551 controls","volume":"237","author":"Suetani","year":"2021","journal-title":"Schizophr. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","article-title":"Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011\u20132022 Update","volume":"40","author":"Rogowska","year":"2022","journal-title":"Drugs Aging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.3748\/wjg.v28.i38.5515","article-title":"Gastrointestinal and liver disease in patients with schizophrenia: A narrative review","volume":"28","author":"Grant","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2021.12.009","article-title":"Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies","volume":"341","author":"Goel","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Islam, S.U., Shehzad, A., Ahmed, M.B., and Lee, Y.S. (2020). Intranasal Delivery of Nanoformulations: A potential way of treatment for neurological disorders. Molecules, 25.","DOI":"10.3390\/molecules25081929"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","article-title":"Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability","volume":"36","author":"Kienitz","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1068495","DOI":"10.3389\/fphar.2022.1068495","article-title":"Systemic and brain delivery of antidiabetic peptides through nasal administration using cell-penetrating peptides","volume":"13","author":"Maeng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"979682","DOI":"10.3389\/fphar.2022.979682","article-title":"Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects","volume":"13","author":"Rajput","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Alabsi, W., Eedara, B.B., Encinas-Basurto, D., Polt, R., and Mansour, H.M. (2022). Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091870"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Nguyen, T.-T., and Maeng, H.-J. (2022). Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030572"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2017.04.019","article-title":"Nanosystem trends in drug delivery using quality-by-design concept","volume":"256","author":"Li","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Iravani, S., and Varma, R.S. (2022). Advanced Drug Delivery Micro- and Nanosystems for Cardiovascular Diseases. Molecules, 27.","DOI":"10.3390\/molecules27185843"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"114482","DOI":"10.1016\/j.addr.2022.114482","article-title":"Engineering nanosystems to overcome barriers to cancer diagnosis and treatment","volume":"189","author":"Wafa","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zorkina, Y., Abramova, O., Ushakova, V., Morozova, A., Zubkov, E., Valikhov, M., Melnikov, P., Majouga, A., and Chekhonin, V. (2020). Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations. Molecules, 25.","DOI":"10.3390\/molecules25225294"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rabaan, A.A., Bukhamsin, R., AlSaihati, H., Alshamrani, S.A., AlSihati, J., Al-Afghani, H.M., Alsubki, R.A., Abuzaid, A.A., Al-Abdulhadi, S., and Aldawood, Y. (2022). Recent Trends and Developments in Multifunctional Nanoparticles for Cancer Theranostics. Molecules, 27.","DOI":"10.3390\/molecules27248659"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Jampilek, J., and Kralova, K. (2022). Anticancer Applications of Essential Oils Formulated into Lipid-Based Delivery Nanosystems. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122681"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijbiomac.2022.12.087","article-title":"Current nanotechnological strategies using lipids, carbohydrates, proteins and metal conjugates-based carrier systems for diagnosis and treatment of tuberculosis\u2014A review","volume":"227","author":"Usharani","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"112999","DOI":"10.1016\/j.colsurfb.2022.112999","article-title":"Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases","volume":"221","author":"Teixeira","year":"2023","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejpb.2016.12.019","article-title":"Polymeric mixed micelles as nanomedicines: Achievements and perspectives","volume":"113","author":"Cagel","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1021\/acs.chemrev.8b00199","article-title":"Block Copolymer Micelles in Nanomedicine Applications","volume":"118","author":"Cabral","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2147\/IJN.S158696","article-title":"Stimuli-responsive polymeric micelles for drug delivery and cancer therapy","volume":"13","author":"Zhou","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17425255.2021.1862085","article-title":"Assessing the pharmacokinetics and toxicology of polymeric micelle conjugated therapeutics","volume":"17","author":"Thotakura","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2020.09.009","article-title":"Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval","volume":"156","author":"Hwang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Alsaab, H.O., Alharbi, F.D., Alhibs, A.S., Alanazi, N.B., Alshehri, B.Y., Saleh, M.A., Alshehri, F.S., Algarni, M.A., Almugaiteeb, T., and Uddin, M.N. (2022). PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122728"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pontes, A.P., Welting, T.J.M., Rip, J., and Creemers, L.B. (2022). Polymeric Nanoparticles for Drug Delivery in Osteoarthritis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122639"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Afzal, O., Altamimi, A.S.A., Nadeem, M.S., Alzarea, S.I., Almalki, W.H., Tariq, A., Mubeen, B., Murtaza, B.N., Iftikhar, S., and Riaz, N. (2022). Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials, 12.","DOI":"10.3390\/nano12244494"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1039\/D2NA00524G","article-title":"Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson\u2019s disease","volume":"4","author":"Alabrahim","year":"2022","journal-title":"Nanoscale Adv."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Alberto, M., Paiva-Santos, A.C., Veiga, F., and Pires, P.C. (2022). Lipid and Polymeric Nanoparticles: Successful Strategies for Nose-to-Brain Drug Delivery in the Treatment of Depression and Anxiety Disorders. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122742"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chaudhuri, A., Kumar, D.N., Shaik, R.A., Eid, B.G., Abdel-Naim, A.B., Ahmad, A., and Agrawal, A.K. (2022). Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231710068"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Khairnar, S.V., Pagare, P., Thakre, A., Nambiar, A.R., Junnuthula, V., Abraham, M.C., Kolimi, P., Nyavanandi, D., and Dyawanapelly, S. (2022). Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091886"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"114485","DOI":"10.1016\/j.addr.2022.114485","article-title":"Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood\u2013brain barrier (BBB) to manage neurological disorders","volume":"189","author":"Correia","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17425255.2019.1621289","article-title":"Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs","volume":"15","author":"Banerjee","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13543776.2020.1720649","article-title":"Solid lipid nanoparticles: A review on recent perspectives and patents","volume":"30","author":"Paliwal","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kalita, T., Dezfouli, S.A., Pandey, L.M., and Uludag, H. (2022). siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112520"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Juha\u0161\u010dik, M., Kov\u00e1\u010dik, A., and Huerta-\u00c1ngeles, G. (2022). Recent Advances of Hyaluronan for Skin Delivery: From Structure to Fabrication Strategies and Applications. Polymers, 14.","DOI":"10.3390\/polym14224833"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Jacob, S., Nair, A.B., Shah, J., Gupta, S., Boddu, S.H.S., Sreeharsha, N., Joseph, A., Shinu, P., and Morsy, M.A. (2022). Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy\u2014An Overview on Recent Advances. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030533"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1016\/j.xphs.2019.08.027","article-title":"Analyzing Nanotheraputics-Based Approaches for the Management of Psychotic Disorders","volume":"108","author":"Annu","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejpb.2022.11.003","article-title":"Current approaches to facilitate improved drug delivery to the central nervous system","volume":"181","author":"Markiewicz","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Pires, P.C., Paiva-Santos, A.C., and Veiga, F. (2022). Nano and Microemulsions for the Treatment of Depressive and Anxiety Disorders: An Efficient Approach to Improve Solubility, Brain Bioavailability and Therapeutic Efficacy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122825"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Pires, P.C., Paiva-Santos, A.C., and Veiga, F. (2022). Antipsychotics-Loaded Nanometric Emulsions for Brain Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102174"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.xphs.2017.03.042","article-title":"Recent Update on Nanoemulgel as Topical Drug Delivery System","volume":"106","author":"Choudhury","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Taha, M., Alhakamy, N.A., Ahmad, M.Z., Fatima, S., Ahmed, N., Alyazedi, F.M., Karim, S., and Ahmad, J. (2022). Nanogels as Potential Delivery Vehicles in Improving the Therapeutic Efficacy of Phytopharmaceuticals. Polymers, 14.","DOI":"10.3390\/polym14194141"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijpharm.2017.04.068","article-title":"Potential and future scope of nanoemulgel formulation for topical delivery of lipophilic drugs","volume":"526","author":"Sengupta","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Pires, P.C., Rodrigues, M., Alves, G., and Santos, A.O. (2022). Strategies to Improve Drug Strength in Nasal Preparations for Brain Delivery of Low Aqueous Solubility Drugs. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030588"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2022.12.013","article-title":"Liposome-based diagnostic and therapeutic applications for pancreatic cancer","volume":"157","author":"Raza","year":"2023","journal-title":"Acta Biomater."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Losada-Barreiro, S., Sezgin-Bayindir, Z., Paiva-Martins, F., and Bravo-D\u00edaz, C. (2022). Biochemistry of Antioxidants: Mechanisms and Pharmaceutical Applications. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123051"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Nogueira","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ajps.2022.11.002","article-title":"Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment","volume":"17","author":"He","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.015","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications","volume":"144","author":"Chen","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"122535","DOI":"10.1016\/j.ijpharm.2022.122535","article-title":"Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis","volume":"631","author":"Gomes","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102637","DOI":"10.1016\/j.nano.2022.102637","article-title":"Neuroprotective effects of niosomes loaded with thymoquinone in the cerebral ischemia model of male Wistar rats","volume":"48","author":"Nemati","year":"2023","journal-title":"Nanomedicine: Nanotechnology, Biol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.2147\/IJN.S384494","article-title":"Novel Mucoadhesive Chitosomes as a Platform for Enhanced Oral Bioavailability of Cinnarizine","volume":"17","author":"Oransa","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ajps.2018.05.007","article-title":"Vesicular nanocarrier based treatment of skin fungal infections: Potential and emerging trends in nanoscale pharmacotherapy","volume":"14","author":"Verma","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2017.07.035","article-title":"Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions","volume":"268","author":"Lalu","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Alharbi, W.S., Hareeri, R.H., Bazuhair, M., Alfaleh, M.A., Alhakamy, N.A., Fahmy, U.A., Alamoudi, A.A., Badr-Eldin, S.M., Ahmed, O.A., and AlGhamdi, S.A. (2022). Spanlastics as a Potential Platform for Enhancing the Brain Delivery of Flibanserin: In Vitro Response-Surface Optimization and In Vivo Pharmacokinetics Assessment. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122627"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1208\/s12249-022-02217-9","article-title":"Spanlastics a Novel Nanovesicular Carrier: Its Potential Application and Emerging Trends in Therapeutic Delivery","volume":"23","author":"Ansari","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"120301","DOI":"10.1016\/j.lfs.2022.120301","article-title":"Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs","volume":"291","author":"Khan","year":"2022","journal-title":"Life Sci."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Akhter, H., Ahmad, I., Alshahrani, M.Y., Al-Harbi, A.I., Khalilullah, H., Afzal, O., Altamimi, A.S.A., Ullah, S.N.M.N., Ojha, A., and Karim, S. (2022). Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System. Gels, 8.","DOI":"10.3390\/gels8020082"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"121862","DOI":"10.1016\/j.ijpharm.2022.121862","article-title":"Review of nanosuspension formulation and process analysis in wet media milling using microhydrodynamic model and emerging characterization methods","volume":"623","author":"Tian","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"114582","DOI":"10.1016\/j.addr.2022.114582","article-title":"Novel drug delivery systems for the management of dry eye","volume":"191","author":"Nagai","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1208\/s12249-016-0552-9","article-title":"Quetiapine Nanoemulsion for Intranasal Drug Delivery: Evaluation of Brain-Targeting Efficiency","volume":"18","author":"Boche","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.07.050","article-title":"Response surface optimization, Ex vivo and In vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone","volume":"530","author":"Abdelrahman","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1567201815666181011121750","article-title":"Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study","volume":"16","author":"Qureshi","year":"2018","journal-title":"Curr. Drug Deliv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijpharm.2017.05.051","article-title":"Parenteral nanoemulsions of risperidone for enhanced brain delivery in acute psychosis: Physicochemical and in vivo performances","volume":"533","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejps.2017.03.050","article-title":"Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects","volume":"104","author":"Joseph","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/21691401.2016.1160402","article-title":"Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles","volume":"45","author":"Natarajan","year":"2016","journal-title":"Artif. Cells, Nanomedicine, Biotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2018.02.010","article-title":"DoE based Olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model","volume":"541","author":"Joseph","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12249-018-1213-y","article-title":"Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies","volume":"20","author":"Gadhave","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/08982104.2019.1610435","article-title":"Surface modified niosomes of olanzapine for brain targeting via nasal route; preparation, optimization, and in vivo evaluation","volume":"30","author":"Khallaf","year":"2019","journal-title":"J. Liposome Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ijbiomac.2017.11.031","article-title":"Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment","volume":"108","author":"Singh","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"119499","DOI":"10.1016\/j.ijpharm.2020.119499","article-title":"Preparation, characterization, and optimization of asenapine maleate mucoadhesive nanoemulsion using Box-Behnken design: In vitro and in vivo studies for brain targeting","volume":"586","author":"Kumbhar","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.xphs.2019.05.001","article-title":"Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies","volume":"108","author":"Jazuli","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s13346-019-00702-6","article-title":"Exploring micellar-based polymeric systems for effective nose-to-brain drug delivery as potential neurotherapeutics","volume":"10","author":"Pokharkar","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40199-019-00281-4","article-title":"Intranasal Zotepine Nanosuspension: Intended for improved brain distribution in rats","volume":"27","author":"Pailla","year":"2019","journal-title":"DARU J. Pharm. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"121050","DOI":"10.1016\/j.ijpharm.2021.121050","article-title":"Nose-to-brain delivery of amisulpride-loaded lipid-based poloxamer-gellan gum nanoemulgel: In vitro and in vivo pharmacological studies","volume":"607","author":"Gadhave","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"120474","DOI":"10.1016\/j.ijpharm.2021.120474","article-title":"Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies","volume":"600","author":"Patel","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.xphs.2021.01.021","article-title":"Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery","volume":"110","author":"Kumbhar","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"119148","DOI":"10.1016\/j.ijpharm.2020.119148","article-title":"Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson\u2019s disease","volume":"579","author":"Bhattamisra","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Elsawy, H., Sedky, A., Taleb, M.F.A., and El-Newehy, M.H. (2022). Antidiabetic Wound Dressing Materials Based on Cellulosic Fabrics Loaded with Zinc Oxide Nanoparticles Synthesized by Solid-State Method. Polymers, 14.","DOI":"10.3390\/polym14112168"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/2\/678\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:38:58Z","timestamp":1760121538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/2\/678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":113,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["pharmaceutics15020678"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15020678","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}